Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis Buys 10,000 Shares

Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis acquired 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were acquired at an average cost of $4.70 per share, with a total value of $47,000.00. Following the transaction, the director now directly owns 77,267 shares in the company, valued at $363,154.90. The trade was a 14.87 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Rezolute Price Performance

RZLT opened at $4.53 on Friday. The company has a market capitalization of $274.20 million, a P/E ratio of -3.71 and a beta of 1.10. The firm’s fifty day moving average price is $4.84 and its two-hundred day moving average price is $4.91. Rezolute, Inc. has a fifty-two week low of $1.49 and a fifty-two week high of $6.19.

Rezolute (NASDAQ:RZLT) last issued its earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. On average, equities research analysts expect that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Institutional Investors Weigh In On Rezolute

Institutional investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC raised its holdings in shares of Rezolute by 10.9% in the 4th quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company’s stock worth $14,004,000 after buying an additional 280,861 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in Rezolute by 699.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,525,883 shares of the company’s stock valued at $12,377,000 after acquiring an additional 2,210,038 shares during the period. Woodline Partners LP grew its position in Rezolute by 2,817.1% in the fourth quarter. Woodline Partners LP now owns 1,089,345 shares of the company’s stock valued at $5,338,000 after acquiring an additional 1,052,002 shares during the period. Susquehanna International Group LLP raised its stake in Rezolute by 749.0% during the fourth quarter. Susquehanna International Group LLP now owns 893,601 shares of the company’s stock worth $4,379,000 after acquiring an additional 788,349 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Rezolute by 19.8% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,223 shares of the company’s stock valued at $2,578,000 after acquiring an additional 86,990 shares during the period. 82.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RZLT has been the topic of several recent analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. Craig Hallum raised shares of Rezolute to a “strong-buy” rating in a research report on Tuesday, February 4th. JMP Securities increased their price target on shares of Rezolute from $8.00 to $9.00 and gave the company a “market outperform” rating in a report on Thursday, February 13th. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research report on Thursday, February 13th. Finally, Wedbush reaffirmed an “outperform” rating and set a $112.00 price objective on shares of Rezolute in a research report on Monday, November 4th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $24.38.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.